This report aims to provide detailed insights into the NGS-based RNA-sequencing market. It provides valuable information on
the type, procedure, application, and region in the market. Furthermore, the
information for these segments, by region, is also presented in this report.
Leading players in the market are profiled to study their product offerings and
understand the strategies undertaken by them to be competitive in this market.
Expected
Revenue Growth:
The NGS-based RNA-sequencing industry size is projected to reach USD 4.2 billion by 2024
from USD 1.7 billion in 2019, at a CAGR of 20.0% during the
forecast period.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=102977816
Key Factors Driving Market Growth:
Market growth is driven mainly by the advantages of RNA-seq over conventional
technologies; an increasing number of RNA-seq grants; rising number of research
activities involving RNA-seq; and rapid growth in precision medicine market.
The expression profiling analysis segment accounted for the largest
share of the NGS-based RNA-sequencing industry, by application, in 2018
Based on application, the NGS-Based RNA-Sequencing Market is segmented into
expression profiling analysis, small RNA sequencing, De Novo transcriptome
assembly, and variant calling & transcriptome epigenetics. In 2018, the
expression profiling analysis segment accounted for the largest share of the
RNA Sequencing Market. The dominant market position of this segment is
attributed mainly to the increasing prevalence of metabolic disorders, multiple
sclerosis, and other diseases. These factors will continue to propel the demand
for expression profiling analysis to provide specific treatment options in the
RNA Sequencing market during the forecast period.
The nanopore segment is expected to register the highest growth in the
NGS-based RNA-sequencing market, by type, during the forecast period
Based on technology, the NGS-based RNA-sequencing industry is segmented into
sequencing by synthesis, ion semiconductor sequencing, single molecular
real-time sequencing, and nanopore sequencing. Nanopore sequencing technology
registers the highest growth rate in the market as it is the only sequencing
technology with direct RNA sequencing capabilities and facilitates sequencing
of full-length RNA strands and modified RNA nucleotides using a simple library
prep, without the need of conversion to double-stranded DNA.
North America dominated
the NGS-based RNA-sequencing market
North America accounted
for the largest share of RNA Sequencing market in 2018. The large share of this
region is the growing prevalence of target diseases, government support through
funds for genomics research, advancements in RNA-Seq products, increasing
research on cancer & inherited rare diseases, and the strong presence of
key players such as Illumina (US), Thermo Fisher (US), and Agilent
Technologies (US) in this region.
Request For Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=102977816
Key Players:
Illumina (US), Thermo Fischer Scientific (US) and Oxford Nanopore (UK), Agilent
Technologies, Inc. (US), BGI (China),
PerkinElmer Inc. (US), QIAGEN (Germany),
Eurofins Scientific (Luxembourg),
F. Hoffmann-La Roche Ltd (Switzerland),
Takara Bio Inc. (Japan),
GENEWIZ, Inc. (US), Hamilton Company (US), Macrogen (South Korea), Zymo Research (US), and Tecan
Genomics, Inc. among others are the major players operating in the NGS-based
RNA-sequencing market.
Illumina dominates the RNA sequencing market with its technologically
advanced & innovative platforms and associated sequencing products. The
company’s product portfolio includes a wide range of highly interconnected
products, including sequencing, genotyping, gene expression, and molecular
diagnostic products. Illumina also offers NGS-based RNA sequencing services
which further strengthens its market position. Over the past three years,
Illumina has launched several products in the market.